Acquisition Opportunity Alderley Analytical has been acquired by Synexa Life Sciences as of October 2024, indicating potential alignment or collaboration opportunities within a larger bioanalytic services network and access to new client cross-sell avenues.

CRO Full-Spectrum As a GLP and GCP accredited independent bioanalytical CRO supporting discovery to late-stage development, there is a strong sales angle for offering integrated bioanalytical services to pharmaceutical and biotech firms seeking single-provider continuity across projects.

Biopharma Focus Their expertise spans small and large molecules, peptides, biologics, and biomarkers, enabling targeted outreach to biopharma programs needing specialized bioanalysis to accelerate regulatory submissions and improve data quality.

Flexible Partner Emphasize their commitment to flexible, responsive service, novel method development, and on-time delivery with clear communication, which can be positioned to win trials with tight timelines or complex regulatory requirements.

Growth Levers Leverage their regional presence in Alderley Park, UK, combined with a scalable CRO model and modest funding, to approach mid-market biotech firms seeking cost-effective, high-quality bioanalysis without large CROs, plus potential cross-sell with Synexa’s network.